Are Sweet Dreams Made of These? Understanding the Relationship Between Sleep and Cannabis Use

Author(s):  
Dalton Edwards ◽  
Francesca M. Filbey
2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Lydia Q. Ong ◽  
John Bellettiere ◽  
Citlali Alvarado ◽  
Paul Chavez ◽  
Vincent Berardi

Abstract Background Prior research examining the relationship between cannabis use, sedentary behavior, and physical activity has generated conflicting findings, potentially due to biases in the self-reported measures used to assess physical activity. This study aimed to more precisely explore the relationship between cannabis use and sedentary behavior/physical activity using objective measures. Methods Data were obtained from the 2005–2006 National Health and Nutrition Examination Survey. A total of 2,092 participants (ages 20–59; 48.8% female) had accelerometer-measured sedentary behavior, light physical activity, and moderate-to-vigorous physical activity. Participants were classified as light, moderate, frequent, or non-current cannabis users depending on how often they used cannabis in the previous 30 days. Multivariable linear regression estimated minutes in sedentary behavior/physical activity by cannabis use status. Logistic regression modeled self-reported moderate-to-vigorous physical activity in relation to current cannabis use. Results Fully adjusted regression models indicated that current cannabis users’ accelerometer-measured sedentary behavior did not significantly differ from non-current users. Frequent cannabis users engaged in more physical activity than non-current users. Light cannabis users had greater odds of self-reporting physical activity compared to non-current users. Conclusions This study is the first to evaluate the relationship between cannabis use and accelerometer-measured sedentary behavior and physical activity. Such objective measures should be used in other cohorts to replicate our findings that cannabis use is associated with greater physical activity and not associated with sedentary behavior in order to fully assess the potential public health impact of increases in cannabis use.


Author(s):  
Rachel Herold ◽  
Rachel Boykan ◽  
Allison Eliscu ◽  
Héctor E. Alcalá ◽  
Maciej L. Goniewicz

Nicotine and cannabis use are common among adolescents and may be associated with behavioral problems, poor academic outcomes and use disorders. The goals of this analysis were the following: (1) Describe the influence of friends’ nicotine and cannabis smoking and vaping on self-reported use. (2) Describe the relationship between friends’ nicotine and cannabis use on participants’ urinary biomarkers of nicotine (cotinine) and cannabis (11-nor-9-carboxy-Δ⁹tetrahydrocannabinol=THC-COOH). This is a secondary analysis of survey and biomarker data collected in adolescents aged 12–21 between April 2017 and April 2018, in Long Island, New York. Bivariate and multivariable analyses were conducted using SPSS 26. A cutoff value of ≥10 ng/mL was used to signify recent usage for urinary cotinine and THC-COOH levels. Over one-third of the 517 surveyed adolescents reported using tobacco and one-third reported using cannabis. A significant relationship between friends’ substance use and self-use was found. For both tobacco and cannabis, over 90% (p < 0.01) of participants with urinary biomarker levels above cutoff had friends who used the respective substance. Friends’ nicotine and friends’ cannabis use were each independently associated with urinary biomarker levels for those substances (for nicotine, beta = 88.29, p = 0.03; for cannabis, beta = 163.58, p = 0.03). Friends’ use of nicotine and cannabis is associated with adolescents’ intake, as well as the physiological exposure to those substances. These findings underscore the importance of including peer influence in the discussion with adolescents about tobacco and cannabis use.


2020 ◽  
Vol 11 ◽  
Author(s):  
Hollis C. Karoly ◽  
Raeghan L. Mueller ◽  
Chrysta C. Andrade ◽  
Kent E. Hutchison

Cannabis is commonly used among people who drink alcohol, but findings are mixed regarding the direction of this relationship. The type of cannabis used [high-cannabidiol (CBD) vs. high-delta-9tetrahydrocannabinol (THC)] and motives for use (i.e., whether cannabis is used to treat a medical condition) may influence the relationship between cannabis and drinking. Specifically, CBD has shown preclinical promise in reducing alcohol consumption, and medical cannabis users report using cannabis to reduce drinking. This study leverages survey data from cannabis users who drink alcohol (N = 533). Respondents were categorized as using cannabis to treat (CTT) a medical condition or as individuals whose cannabis use is not intended to treat (NCTT) a medical condition and grouped based on the THC/CBD ratio of the flower or edible cannabis they typically use (e.g., “High-THC/CBD,” “Medium-THC/CBD” and “Low-THC/CBD”). The CTT group (n = 412) reported drinking significantly less frequently than the NCTT group (n = 121). Cannabinoid content of flower cannabis was associated with alcohol consumed on cannabis-use days, such that individuals in the High-THC/CBD group drink more on cannabis-use days compared to the Medium-THC/CBD group. Cannabinoid content of edible cannabis was associated with drinks per drinking occasion, such that the High-THC/CBD group consumed the most drinks and the Low-THC/CBD group consumed the fewest. For both edible and flower groupings, higher-THC/CBD cannabis was associated with more frequent co-use than lower-THC/CBD cannabis. Results suggest that whether someone uses cannabis to treat a medical condition may impact their drinking frequency, and the cannabinoid content in flower and edible cannabis impacts alcohol consumption.


2017 ◽  
Vol 62 (11) ◽  
pp. 3603-3617 ◽  
Author(s):  
James C. McCutcheon ◽  
Stephen J. Watts

Gateway theory has been the source of much debate in both the research literature and public policy. Support for gateway sequencing has been mixed, especially in research that has considered the role of criminological variables in the etiology of substance use. For example, limited prior research has observed as important in gateway sequencing the effects of severe stressors. Data from the National Longitudinal Study of Adolescent to Adult Health are utilized to test gateway theory and examine whether severe stressors affect the relationship between frequency of cannabis use and later use of other illicit drugs (OIDs). Findings suggest that while frequency of cannabis use does increase the likelihood of later use of OIDs, this relationship may be the result of the common cause of experiencing severe stress. Implications of the findings are discussed.


2017 ◽  
Vol 37 (suppl_1) ◽  
Author(s):  
Adeyinka C Adejumo ◽  
Samson Alliu ◽  
Oluwole M Adegbala ◽  
Nnaemeka E Onyeakusi ◽  
Tokunbo O Ajayi ◽  
...  

Introduction: Cannabis is a commonly utilized recreational substance which contains numerous bioactive agents. As more states legalize the use of marijuana, it’s effect on various disease conditions is expected to become more pronounced. Cannabis’ anti-inflammatory effects could suppress pro-inflammatory conditions. For example, chronic inflammation with extracellular matrix degradation resulting in weakness and abnormal dilatation of the aortic wall is a hallmark of Aortic Aneurysm. We, therefore, hypothesized that cannabis users would have less prevalence of aortic aneurysms. Objective: To identify the relationship between chronic cannabis use (CU) and diagnosis of aortic aneurysms (AA) among hospitalized patients. Methods: After selecting patients who were 55 years and above from 2012 to 2014 National Inpatient Sample database, we identified those who had a diagnosis of Aortic Aneurysm and those who utilize Cannabis. We then stratified the CU into two groups: nondependent (NDU) and dependent users (DU). Using logistic regression, we estimated the Odds Ratio (AOR) after controlling for numerous factors. Results: In our total 10,461,694 sample, 99.6% (10,419,972) are non-users, 0.37% (38,514) are nondependent users and 0.03% (3,208) are dependent users. About 3.21% (336,202) of the patients had a diagnosis of AA versus 96.79% (10,125,492) without a diagnosis of AA. Compared to non-users of cannabis, the odds of AA is about 35% less among CU (AOR 0.66[0.62-0.71]), 40% less among DU (aOR 0.58[0.44-0.76]), and 33% less among NDU (AOR 0.67[0.62-0.72]). The odds of AA was lower in females (AOR 0.61[0.60-0.610]), but higher in many conditions such as: among >=65 years (AOR 1.16[1.15-1.17]), tobacco users (AOR 1.18[1.17-1.19]), predisposing hereditary conditions (AOR 5.31[4.60-6.13]), and atherosclerosis (AOR 3.04[3.00-3.08]). Conclusions: Our result shows that Cannabis use is associated with less occurrence of AA. Cannabidiol, an anti-inflammatory alkaloid in Cannabis could potentially suppress the release of proteolytic inflammatory mediators which might be responsible for the gradual weakening of the vascular walls. We recommend more basic research to evaluate this effect of Cannabidiol.


Author(s):  
Nina Pocuca ◽  
T Jordan Walter ◽  
Arpi Minassian ◽  
Jared W Young ◽  
Mark A Geyer ◽  
...  

Abstract Background Older adults (≥50 years) represent the fastest-growing population of people who use cannabis, potentially due to the increasing promotion of cannabis as medicine by dispensaries and cannabis websites. Given healthy aging and cannabis use are both associated with cognitive decline, it is important to establish the effects of cannabis on cognition in healthy aging. Objective This systematic scoping review used preferred reporting items for systematic reviews and meta-analyses guidelines to critically examine the extent of literature on this topic and highlight areas for future research. Method A search of six databases (PubMed, EMBASE, PsycINFO, Web of Science, Family and Society Studies Worldwide, and CINAHL) for articles published by September 2019, yielded 1,014 unique results. Results Six articles reported findings for older populations (three human and three rodent studies), highlighting the paucity of research in this area. Human studies revealed largely null results, likely due to several methodological limitations. Better-controlled rodent studies indicate that the relationship between ∆9-tetrahydrocannabinol (THC) and cognitive function in healthy aging depends on age and level of THC exposure. Extremely low doses of THC improved cognition in very old rodents. Somewhat higher chronic doses improved cognition in moderately aged rodents. No studies examined the effects of cannabidiol (CBD) or high-CBD cannabis on cognition. Conclusions This systematic scoping review provides crucial, timely direction for future research on this emerging issue. Future research that combines neuroimaging and cognitive assessment would serve to advance understanding of the effects of age and quantity of THC and CBD on cognition in healthy aging.


2020 ◽  
Vol 1 (1) ◽  
Author(s):  
Melanie Blair Thies ◽  
Pamela DeRosse ◽  
Deepak K Sarpal ◽  
Miklos Argyelan ◽  
Christina L Fales ◽  
...  

Abstract Antipsychotic (AP) medications are the mainstay for the treatment of schizophrenia spectrum disorders (SSD), but their efficacy is unpredictable and widely variable. Substantial efforts have been made to identify prognostic biomarkers that can be used to guide optimal prescription strategies for individual patients. Striatal regions involved in salience and reward processing are disrupted as a result of both SSD and cannabis use, and research demonstrates that striatal circuitry may be integral to response to AP drugs. In the present study, we used functional magnetic resonance imaging (fMRI) to investigate the relationship between a history of cannabis use disorder (CUD) and a striatal connectivity index (SCI), a previously developed neural biomarker for AP treatment response in SSD. Patients were part of a 12-week randomized, double-blind controlled treatment study of AP drugs. A sample of 48 first-episode SSD patients with no more than 2 weeks of lifetime exposure to AP medications, underwent a resting-state fMRI scan pretreatment. Treatment response was defined a priori as a binary (response/nonresponse) variable, and a SCI was calculated in each patient. We examined whether there was an interaction between lifetime CUD history and the SCI in relation to treatment response. We found that CUD history moderated the relationship between SCI and treatment response, such that it had little predictive value in SSD patients with a CUD history. In sum, our findings highlight that biomarker development can be critically impacted by patient behaviors that influence neurobiology, such as a history of CUD.


2019 ◽  
Author(s):  
Carmen Logie ◽  
Ying Wang ◽  
Mina Kazemi ◽  
Brenda Gagnier ◽  
Tracey Conway ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document